Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1

Journal of Virology

Volumn 79, Issue 12, 2005, Pages 7728-7737

  Stratov, Ivan ^a   Dale, Jane ^a   Chea, Socheata ^a   McCluskey, James ^a   Kent, Stephen J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CD8 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; EPITOPE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; SYNTHETIC PEPTIDE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEUKOCYTE COUNT; MACACA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MACACA NEMESTRINA; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAE; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 19944365907     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.12.7728-7737.2005     Document Type: Article

References (36)

1. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
2. Ammaranond, P., P. Cunningham, R. Oelrichs, K. Suzuki, C. Harris, L. Leas, A. Grulich, D. A. Cooper, and A. D. Kelleher. 2003. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J. Clin. Virol. 26:153-161.
3. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, D. C. Montefiori, M. G. Lewis, S. M. Wolinsky, and N. L. Letvin. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335-339.
4. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A. Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S. Gelman, D. C. Montefiori, M. G. Lewis, E. A. Emini, J. W. Shiver, and N. L. Letvin. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486-492.
5. Birch, C., T. Middleton, G. Hales, D. Cooper, M. Law, S. Crowe, J. Hoy, and S. Emery. 2003. Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing. J. Acquir. Immune Defic. Syndr. 32:57-61.
6. Brindeiro, R. M., R. S. Diaz, E. C. Sabino, M. G. Morgado, I. L. Pires, L. Brigido, M. C. Dantas, D. Barreira, P. R. Teixeira, and A. Tanuri. 2003. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17:1063-1069.
7. Chang, K. M., N. H. Gruener, S. Southwood, J. Sidney, G. R. Pape, F. V. Chisari, and A. Sette. 1999. Identification of HLA-A3- and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J. Immunol. 162:1156-1164.
8. Chea, S., C. J. Dale, R. De Rose, I. A. Ramshaw, and S. J. Kent. 2005. Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J. Virol. 79:3748-3757.
9. Dale, C. J., R. De Rose, I. Stratov, S. Chea, D. C. Montefiori, S. Thomson, I. A. Ramshaw, B. E. Coupar, D. B. Boyle, M. Law, and S. J. Kent. 2004. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J. Virol. 78:13819-13828.
10. Hansen, J. A., and B. Dupont. 2004. HLA 2004: immunobiology of the human MHC. In The proceedings of the 13th International Histocompatibility Workshop and Congress, vol. I and II. IHWG Press, Seattle, Wash.
11. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283:2417-2426.
12. Karlsson, A. C., S. G. Deeks, J. D. Barbour, B. D. Heiken, S. R. Younger, R. Hoh, M. Lane, M. Sallberg, G. M. Ortiz, J. F. Demarest, T. Liegler, R. M. Grant, J. N. Martin, and D. F. Nixon. 2003. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protcase gene. J. Virol. 77:6743-6752.
13. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
14. Korber, B. T. M., C. Brander, B. F. Haynes, R. Koup, C. Kuiken, J. P. Moore, B. D. Walker, and D. I. Watkins (ed.). 2002. HIV molecular immunology. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico. [Online.]
15. Maecker, H. T., H. S. Dunn, M. A. Suni, E. Khatamzas, C. J. Pitcher, T. Bunde, N. Persaud, W. Trigona, T. M. Fu, E. Sinclair, B. M. Bredt, J. M. McCune, V. C. Maine, F. Kern, and L. J. Picker. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255:27-40.
16. Menendez-Arias, L., M. A. Martinez, M. E. Quinones-Mateu, and J. Martinez-Picado. 2003. Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr. Drug Targets Infect. Disord. 3:355-371.
17. Moore, C. B., M. John, I. R. James, F. T. Christiansen, C. S. Witt, and S. A. Mallal. 2002. Evidence of HIV-1 adaptation to HLA-restrictcd immune responses at a population level. Science 296:1439-1443.
18. Muzammil, S., P. Ross, and E. Freire. 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42:631-638.
19. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
20. Ohtaka, H., A. Schon, and E. Freire. 2003. Multidrug resistance to HlV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 42:13659-13666.
21. Propato, A., E. Schiaffella, E. Vicenzi, V. Francavilla, L. Baloni, M. Paroli, L. Finocchi, N. Tanigaki, S. Ghezzi, R. Ferrara, R. Chesnut, B. Livingston, A. Sette, R. Paganelli, F. Aiuti, G. Poli, and V. Barnaba. 2001. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum. Immunol. 62:561-576.
22. Richman, D. D. 2001. HIV chemotherapy. Nature 410:995-1001.
23. Richman, D. D., and S. Staszewski. 2000. HIV drug resistance and its implications for antiretroviral treatment and strategies, 2nd ed. International Medical Press Ltd., London, United Kingdom.
24. Robinson, H. L., D. C. Montefiori, R. P. Johnson, K. H. Manson, M. L. Kalish, J. D. Lifson, T. A. Rizvi, S. Lu, S. L. Hu, G. P. Mazzara, D. L. Panicali, J. G. Herndon, R. Glickman, M. A. Candido, S. L. Lydy, M. S. Wyand, and H. M. McClure. 1999. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:526-534.
25. Roge, B. T., T. L. Katzenstein, N. Obel, H. Nielsen, O. Kirk, C. Pedersen, L. Mathiesen, J. Lundgren, and J. Gerstoft. 2003. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8:173-182.
26. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
27. Samri, A., G. Haas, J. Duntze, J. M. Bouley, V. Calvez, C. Katlama, and B. Autran. 2000. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J. Virol. 74:9306-9312.
28. Schmitt, M., E. Harrer, A. Goldwich, M. Bauerle, I. Graedner, J. R. Kalden, and T. Harrer. 2000. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 14:653-658.
29. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, et al. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
30. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
31. Sidney, J., H. M. Grey, S. Southwood, E. Celis, P. A. Wentworth, M. F. del Guercio, R. T. Kubo, R. W. Chesnut, and A. Sette. 1996. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum. Immunol. 45:79-93.
32. Sune, C., L. Brennan, D. R. Stover, and T. Klimkait. 2004. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure. Clin. Microbiol. Infect. 10:119-126.
33. Threlkeld, S. C., P. A. Wentworth, S. A. Kalams, B. M. Wilkes, D. J. Ruhl, E. Keogh, J. Sidney, S. Southwood, B. D. Walker, and A. Sette. 1997. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class 1 A3-like superfamily: implications for vaccine development. J. Immunol. 159:1648-1657.
34. Wainberg, M. A., H. Salomon, Z. Gu, J. S. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, et al. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-relatcd complex. AIDS 9:351-357.
35. White, K. L., N. A. Margot, T. Wrin, C. J. Petropoulos, M. D. Miller, and L. K. Naeger. 2002. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46:3437-3446.
36. Zhong, P., L. Kang, Q. Pan, F. Konings, S. Burda, L. Ma, Y. Xue, X. Zheng, Z. Jin, and P. Nyambi. 2003. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China. J. Acquiv. Immune Defic. Syndr. 34:91-101.